New frontiers in the treatment of systemic juvenile idiopathic arthritis

Systemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines,...

Descripción completa

Detalles Bibliográficos
Autores principales: Canny, Susan, Mellins, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482342/
https://www.ncbi.nlm.nih.gov/pubmed/28690841
http://dx.doi.org/10.12688/f1000research.11327.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482342/
https://www.ncbi.nlm.nih.gov/pubmed/28690841
http://dx.doi.org/10.12688/f1000research.11327.1

Ejemplares similares